Navigation Links
Brookhaven Lab and BioSET Inc. patent improved growth factor technology
Date:7/13/2010

UPTON, NY Brookhaven Science Associates, the company that manages the U.S. Department of Energy's Brookhaven National Laboratory, and Biosurface Engineering Technologies, Inc. (BioSET) of Rockville, Maryland, have been issued a U.S. patent for an improved second-generation technology for designing synthetic peptides that are important for tissue regeneration. These bioactive peptides are designed to communicate growth signals to cells of damaged tissue in order to foster efficient, rapid healing.

BioSET has an exclusive license for producing these peptides, which hold promise for improving the body's healing response in numerous applications of tissue repair. Developed at Brookhaven Lab, these synthetic peptides, known as growth factor analogs, are easier to produce than natural growth factors or growth factors derived from recombinant techniques.

Tom Rouech, BioSET's president, said, "This newly patented technology builds upon our core method for making synthetic biomimedic peptides that we developed with Brookhaven Lab scientists almost a decade ago. We can now make peptides in higher yields, with more purity, and more cost-effectively than we had done previously."

Louis Pea, the principal researcher at Brookhaven Lab who developed the technology with BioSET, added, "This new platform technology will allow us to make multiple variations of peptides, which can lead to numerous applications in tissue repair. For example, bandages can be designed with growth factor analogs to apply to wounds, or coatings for surgical implants can be made for better localized healing. I'm glad that this technology has progressed so well and may benefit many people with soft-tissue injuries." A soft tissue injury results from damage to muscles, ligaments, or tendons.

BioSET has sublicensed the newly patented technology to Tornier, Inc., a global orthopedic company, to develop synthetic peptides for sports medicine applications, with emphasis on rotator cuff, shoulder, knee, and elbow injuries. The company will develop novel soft-tissue grafts with synthetic human growth factor for orthopedic markets.

"Assessing the role of tissue regeneration and clinical testing of the new growth factor analogs is the next step as we bring these important new treatments to surgeons and their patients," Rouech said. "A previously patented growth factor analog, B2A, designed to improve bone repair, is currently in clinical trials for spinal fusion of the lower back and we remain very encouraged by the early results of these studies."

The U.S. Department of Energy's Office of Science, the National Institutes of Health, and BioSET funded the initial research to develop this growth factor technology. One of three patents related to this technology issued to BSA and BioSET, the new patent (US 7,700,563 B2), was issued on April 20, 2010.


'/>"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
Source:Eurekalert

Related medicine news :

1. USF receives patent for technology to improve treatment for neurodegenerative diseases
2. Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
3. Greenway Awarded U.S. Patent For EHR Functionality and Workflow
4. Volumetrics Medical Imaging, LLC and Medison Co., Ltd. Announce Technology License and Settlement of Patent Litigation
5. Mobile and Patented: DATA-TO-CAMERA TOGGLE on handheld device replaces old camera and clipboard approach everywhere! Beats IPAD to camera punch too.....
6. US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications
7. GenomeQuest Upgrades Online Patent Searching
8. "IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do
9. Drug Patents in India Helping Promote Innovation
10. Innovative Patent-pending Shapewear Technology Introduced for Jeans.
11. Wind Power Systems, LLC (WPS) Launches PPM to Raise $2.5M for Earth Friendly Patent Pending "Small Wind" Turbine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology: